002907.SZ
002907.SZ
CNE100003308
PHARSCIN PHARMA
Loading chart...

Company Profile

Chongqing Pharscin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China and internationally. It offers generic drugs, traditional Chinese medicines, and food for special medical purposes in various forms, including tablets, granules, capsules, soft capsules, powders, powder injections, lyophilized powder injections, small-volume injections, chemical raw materials, and traditional Chinese medicine extracts. The company is also involved in the provision of CDMO and CMO services; pharmaceutical technology development services and consulting; wholesale and retail activities; and scientific research and technical services. Its products are used in digestive diseases, central nervous system disorders, and otolaryngology therapeutic areas. The company was incorporated in 1996 and is headquartered in Chongqing, China.

Related stocks

600422.SS
600422.SS • China
KPC PHARMACEUTICALS INC
8.36 CNY
946.93M USD 1Y -40.3%
002038.SZ
002038.SZ • China
SL PHARM
5.76 CNY
885.46M USD 1Y -20.3%
300705.SZ
300705.SZ • China
JIUDIAN
11.23 CNY
840.68M USD 1Y -34%
600488.SS
600488.SS • China
TIANJIN TIANYAO PHARMACEUTICAL
6.47 CNY
1.06B USD 1Y +59%
000566.SZ
000566.SZ • China
HAINAN HAIYAO
4.71 CNY
914.35M USD 1Y -13.7%
688091.SS
688091.SS • China
SHANGHAI YIZHONG PHARMACEUTICAL
36.8 CNY
1.14B USD 1Y -36.9%
002020.SZ
002020.SZ • China
JINGXIN
11.87 CNY
1.53B USD 1Y -41.5%
603538.SS
603538.SS • China
NINGBO MENOVO PHARMACEUTICAL CO
28.45 CNY
1.45B USD 1Y +80%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
51.4% p.a.
Max Drawdown (5Y)
-69.0%
Sharpe Ratio (5Y)
0.06
Beta Factor
-0.22
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 81.3 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (51.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -76.3% in the extended horizon.
ende